Aeterna Zentaris Inc.
(NASDAQ : AEZS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading AEZS News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.11%70.401.0%$912.85m
AMGNAmgen Inc.
1.52%179.220.8%$649.02m
BIIBBiogen Inc.
1.57%293.140.9%$502.27m
CELGCelgene Corporation
0.53%124.171.0%$500.71m
INCYIncyte Corporation
1.29%134.822.3%$450.27m
REGNRegeneron Pharmaceuticals, Inc.
1.48%379.031.9%$339.06m
ALXNAlexion Pharmaceuticals, Inc.
1.54%133.272.0%$303.89m
TSROTESARO, Inc.
-3.92%180.9915.3%$161.43m
ILMNIllumina, Inc.
1.02%169.103.9%$158.58m
EXELExelixis, Inc.
4.11%22.425.5%$141.07m
VRTXVertex Pharmaceuticals Incorporated
0.35%90.942.6%$140.27m
CLVSClovis Oncology, Inc.
3.10%59.6016.4%$119.51m
BMRNBioMarin Pharmaceutical Inc.
0.47%94.373.9%$109.23m
AAgilent Technologies, Inc.
1.25%51.941.7%$107.79m
ACADACADIA Pharmaceuticals Inc.
-2.98%36.9819.0%$94.23m

Company Profile

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Montreal, Canada.